SimpleRx: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://rxmadesimple.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   “The following claims concerning compounded semaglutide and tirzepatide products appear on your website:”

2. 2

   ““Semaglutide (Ozempic)” “Tirzepatide (Zepbound)” “Tirzepatide (generic Zepbound)””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

rxmadesimple.com still resolved on 2026-08-09, but it did not serve a storefront: the page returned was a placeholder headed "Pardon our dust! We're working on something amazing — check back soon!" with no catalogue, no prices and no mention of semaglutide or tirzepatide, and the site's sitemap returned a WordPress "Database Error". That is not evidence the company has closed — a placeholder can precede a relaunch — so we record this as unconfirmed rather than guessing either way.

The three things FDA cited here are not promises, arguments or adjectives — they are the names on the menu. "Tirzepatide (Zepbound)" reads as a helpful gloss, the kind of parenthetical a pharmacy might add so you know what you are looking at, and "Tirzepatide (generic Zepbound)" goes one step further into a word with a specific regulatory meaning that a compounded product does not have. That is what makes this letter useful when you are comparing prices: you can screen a site for overblown promises and still miss this, because the naming happens before any promise is made. The line item itself is doing the persuading. As for the price behind those names, we could not check it — the storefront was a placeholder when we looked, and we have recorded that rather than assumed the rest.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence SimpleRx failed to respond.